Genmed announces Suprafen drug registration with Dutch MEB

Genmed Holding Corp. has announced its next generic drug registration. The Company will file it's dossier for the drug Suprafen, otherwise known as Ibuprofen, with the Dutch Medicines Evaluation Board (MEB) in the coming months. Suprafen is a non-steroidal anti-inflammatory as well as an analgesic.

The European Union's wholesale market for Suprafen, not including hospital or insurance company usage, is approximately €245 million, according to IMS Health. The approval of Genmed's dossier should come sometime next year, according to the Company. Upon approval, the submission shall garner mutual recognition for the following EU countries; Netherlands, Belgium, Luxembourg, Germany, France, Ireland, and the United Kingdom. The Company plans on pursuing a similar distribution strategy to its current Paracetamol license which includes direct sales and private label arrangements.

Genmed Chief Executive Officer, Erwin Bouwens commented on the Company's announcement by saying, "We now have the resources to pursue another drug license and we are preparing the necessary paperwork for our submission. There is a great deal of interest in private label distribution agreements for this drug so we felt it was an appropriate next step for us to get the dossier ready for filing. After our positive experience with obtaining the Paracetamol license we should have a much easier time with the Ibuprofen submission."

Source: Genmed Holding Corp.